NCT02245451已完成1 期
A Single-centre, Open-label Study of Multiple Doses of Tipranavir 500 mg and Ritonavir 200 mg (Twice Daily) on the Pharmacokinetic Characteristics of Methadone Administered as a Single Dose in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 主要终点
- Maximum concentration (Cmax)
研究概览
简要总结
The primary objective of this study is to characterise the effects of tipranavir 500 mg and ritonavir 200 mg (TPV/r; given twice daily) at steady-state on the pharmacokinetics of methadone administered as a single dose in healthy adult volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female healthy volunteers aged at least 18 to 60 years.
- •Clinically normal medical history.
- •Clinically normal findings on physical examination.
- •Clinically normal laboratory values.
- •A Body Mass Index >18.5 and <30 kg/m
- •Able to swallow large capsules without difficulty.
- •Capable of comprehending and communicating effectively with the investigator and staff and of providing written informed consent in accordance with ethics committee and regulatory guidelines.
- •Willing to stay in the study centre for the duration of the study.
- •Willing to abstain from ingesting substances during the study which may alter plasma study drug levels by interaction with the cytochrome P450 system.
- •Willing to abstain from alcohol for 48 hours prior to Visit 1 and for the duration of the study. In addition, Cabernet Sauvignon must not have been ingested within 15 days prior to Visit
- •Willing to abstain from ingesting grapefruit and grapefruit juice for 15 days before Visit 1 and for the duration of the study.
- •Willing to abstain from ingesting Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) for 72 hours before the pharmacokinetic sampling days.
- •Willing to abstain from use of tobacco products for the duration of the study.
- •Urine drug screen negative for illegal non-prescription drugs.
- •Negative HIV serology.
- •Negative for Hepatitis B surface antigen and Hepatitis C
排除标准
- •Any clinically significant disease. (A significant disease was defined as a disease which in the opinion of the investigator may either have put the subject at risk because of participation in the study or a disease which may have influenced the results of the study or the subject's ability to participate in the study.)
- •Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings.
- •Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, triglyceride or glucose greater than the upper limit of normal at Visit
- •Treatment with prohibited medications in the thirty days before the study or during the study or ingestion of drugs of abuse.
- •Treatment with any investigational drug within 90 days of the first dose of study medication.
- •Inability to adhere to the requirements of the protocol (including active substance abuse) as assessed by the investigator.
- •Prior tipranavir use.
- •Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, clarithromycin, rifampin, steroids, and herbal medications) for thirty days prior to Visit
- •Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within fifteen days prior to Visit
- •Ingestion of Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of pharmacokinetics sampling days.
- •Treatment with prescription medicines within thirty days prior to Visit
- •History of gastrointestinal, hepatic, or renal disorders within 60 days prior to Visit
- •Any history of alcohol or drug abuse.
- •Current use of cigarettes defined as greater than 10 cigarettes per day or rolling/pipe tobacco equivalent.
- •Blood or plasma donations within 90 days prior to Visit 1
- •Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/min or >100 beats/min.
- •Subjects with a history of any illness or allergy that, in the opinion of the investigator, might have confounded the results of the study or posed additional risk in administering tipranavir, ritonavir or methadone to the subject.
- •Subjects who had an acute illness within two weeks prior to Visit
- •Subjects who were currently taking any over-the-counter drug within fourteen days prior to Visit 1 or who were currently taking any prescription drug.
- •Hypersensitivity to tipranavir, ritonavir, or methadone.
- •Female subjects who are of reproductive potential and who were pregnant, breastfeeding, had a positive serum B-HCG at Visit 1 or 2, had not been using a barrier contraceptive method for at least three months prior to Study Day 1 or were not willing to use a reliable method of double-barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam) during the study and for thirty days after completion or termination of the study.
研究组 & 干预措施
TPV/r with methadone
Experimental
干预措施: Tipranavir (Drug)
TPV/r with methadone
Experimental
干预措施: Ritonavir (Drug)
TPV/r with methadone
Experimental
干预措施: Methadone (Drug)
结局指标
主要结局
Maximum concentration (Cmax)
时间窗: up to 24 hours after drug administration
Concentration at 6 hours (C6h) of methadone
时间窗: 6 hours after drug administration
concentration at 12 hours (C12h) of tipranavir and ritonavir
时间窗: 12 hours after drug administration
Area under the concentration-time curve for 0 to 24 hours (AUC0-24h) of methadone
时间窗: up to 24 hours after drug administration
Area under the concentration-time curve for 0 to 12 hours (AUC0-12h) of tipranavir and ritonavir
时间窗: up to 12 hours after drug administration
次要结局
- mean residence time (MRT)(up to 24 hours after drug administration)
- Number of participants with adverse events(Up to day 17 after first drug administration)
- apparent terminal half-life (t½)(up to 24 hours after drug administration)
- time to maximum concentration (Tmax)(up to 24 hours after drug administration)
- apparent volume of distribution during the terminal elimination phase divided by the bioavailability factor (Vz/F)(up to 24 hours after drug administration)
- Number of patients with abnormal findings in physical examination(Up to day 17 after first drug administration)
- Number of patients with clinically significant changes in vital signs(Up to day 17 after first drug administration)
- Number of patients with abnormal changes in clinical laboratory parameters(Up to day 17 after first drug administration)
- oral clearance (CL/F)(up to 24 hours after drug administration)
研究者
相似试验
已完成
1 期
Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy VolunteersHealthyNCT02249416Boehringer Ingelheim60
已完成
1 期
Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult VolunteersHealthyNCT02253823Boehringer Ingelheim68
已完成
1 期
Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected SubjectsHIV InfectionsNCT02251223Boehringer Ingelheim208
已完成
1 期
Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy VolunteersHealthyNCT02251145Boehringer Ingelheim49
已完成
1 期
Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy VolunteersHealthyNCT02251132Boehringer Ingelheim113